Background: Comorbid anxiety is common in bipolar disorder (BD) and associated with worse clinical outcomes including increased suicidality. Despite effective psychological treatments for anxiety, research into treating anxiety in BD is underdeveloped. This paper describes a novel psychological intervention to address anxiety in context of bipolar disorder (AIBD).
INTRODUCTION
comorbid anxiety disorder (Ellard et al., 2017) . Although UP was not specifically developed with individuals with BD, it was argued that its focus on emotional dysregulation was likely to make it appropriate for this group. Ellard and colleagues randomized 29 individuals to receive either UP + TAU or TAU alone, with approximately 62% retention to end of treatment follow-up (6 months) and similar treatment satisfaction in both groups. Individuals who received UP + TAU reported greater improvements in anxiety (clinician rated) and depression (selfand clinician rated) than controls.
A key question in developing treatment approaches to anxiety comorbidity is whether to target anxiety diagnoses or symptoms. The latter was chosen here for three reasons: (1) anxiety disorders tend to be highly comorbid, especially in BD (Provencher et al., 2011) and multiple separate interventions for specific anxiety disorders would be inefficient. (2) Anxiety-related distress in BD often does not fit neatly within an anxiety diagnostic category (Hampshire, 2014; Provencher et al., 2011) . (3) Anxiety disorders typically share key elements, including interference with functioning and subjective feelings of anxiety, worry, and tension (Barlow et al., 2010) .
The aim of this study was to test the feasibility and acceptability of the anxiety in context of bipolar disorder (AIBD) intervention using a randomised controlled trial (RCT) design.
METHODS
This study was preregistered (ISRCTN: 84288072), reviewed, and approved by UK NHS Ethics (REC ref: 10/H1015/83) with a published research protocol .
Trial design
A rater-blind individually randomized controlled trial comparing ≤10 sessions of integrated CBT for AIBD plus TAU compared with TAU alone conducted across seven NHS trusts in the North West of England. A nested qualitative study explored feasibility and acceptability.
Participants were randomized by an independent clinical trials unit (MAHSC CTU 9) with randomly sized permuted blocks minimized on gender, number of previous mood episodes (depression and mania: <7, 8-19, or >20) , and current anxiety (Hamilton Anxiety Rating Scale [HAM-A] score: 0-17, 18-24, or >25).
To ensure blindness, researchers were housed separately from therapists and had no involvement in randomization or postrandomization data. Trial participants were instructed to avoid disclosing treatment arm. Unblindings were recorded and an alternate blind research assistant (RA) was allocated.
Recruitment
Participants were recruited (June 2011-May 2012) from NHS mental health and primary care services and voluntary groups. Advertisements in local media and at NHS and non-NHS sites aimed to maximize participant access. All participants provided written informed consent.
Inclusion/exclusion criteria
Inclusion criteria were as follows: (1) DSM-IV (SCID) verified BD diagnosis (First, Spitzer, Gibbon, & Endicott, 1997) , (2) current significant anxiety (HADS-A ≥ 8; Zigmond & Snaith, 1983) , (3) ability to provide informed consent, and (4) ≥ 18 years.
Exclusion criteria were as follows: (1) current mood mixed episode (or last 4 weeks) and (2) current suicidal ideation with intent. Table 1 . In line with the results of these interviews and focus groups, AIBD was developed to be sensitive to the potential impact of anxiety and to offer information and structured psychological support to address collaboratively agreed personalized therapy goals. AIBD was offered flexibly in terms of location (client's home or clinical setting according to client preference) and session duration, with sessions supported by client workbooks including client therapy record and anxiety recovery plans, lived experience accounts of anxiety and BD, and information about additional resources and support.
Intervention
Specific CBT strategies were drawn from best practice guidance from NICE in relation to anxiety and BD available during the period of AIBD development NICE, 2004 NICE, , 2005a NICE, , 2005b NICE, , 2006 . Important AIBD elements include flexible engagement, reviewing of positive experiences and coping as well as difficulties, and a flexible formulation-driven approach to individual therapy plan development.
The individualized formulation-driven approach took into account level of engagement and motivation and explored links between anxiety and bipolar experiences, including issues around functioning, to elicit personally valued treatment goals. On the basis of this information, consideration was given to the client's key anxiety concerns and which of these to target as goals within therapy. The specific intervention plan in each case was guided by the individual formulation and incorporated appropriate cognitive behavioral strategies focused on addressing anxiety experiences and consequent behavior.
This included CBT to facilitate adaptive approaches to dealing with anxiety and, where appropriate, addressing the impact of depressed or elevated mood on these issues as well. Typically, the CBT approach included learning more about the nature of their anxiety symptoms and developing coping strategies for dealing with them using CBT techniques including graded exposure/interoceptive exposure, relaxation and breathing techniques, cognitive restructuring, behavioral experiments, thought monitoring/challenge, and adaptive problem solving. Where it was clear that mood instability and relapse were strongly associated with anxiety difficulties, mood-monitoring techniques, detection of early warning signs for problematic mood changes and coping strategies in relation to these early warning signs, and regularization of routine and mood-related problem-solving strategies were also a feature of therapy. The information from all phases was
TA B L E 1 Summary treatment development information from individual interviews and focus groups

Individual interviews Issues Quotes
Therapy experiences
Recognition of the impact anxiety can have. Collaborate to personalize individual therapy goals "the GP understands nothing about anxiety…, tells them there's something else wrong with them … Or gives them the wrong medication er … doesn't realise how serious the anxiety is so doesn't recommend them to a psychiatrist or a psychologist." AA018 "I felt worried more … and more … and I felt more unable to disclose information, because I didn't know if they were on my side you know. So I think it's very important to establish a bit of trust …A054 "I just want to know why": Knowledge as power Importance of specific information about the nature of anxiety and relationships to mood experiences ".. I always think knowledge is, knowledge is power. And, and the more I know, the more better able I am to handle a situation which is not within my control" AA018
Limitations of drug treatment
Drug treatments for anxiety seen as sometimes unhelpful and even worsening anxiety. Strong support for psychological approaches.
"… medication is needed but medication alone doesn't do anything for anxiety, and it is just not active at all." AA054 "they tried me on a, a mixture of medication … and the first one actually made me … a damn sight worse…." AA008
Cognitive and behavioural strategies
Importance of having effective approaches to deal with anxiety-related thoughts and behaviour awareness that these approaches are difficult to identify or apply without structured support "When you are dealing with emotions like I was dealing with, it's hard enough just to cope with that, never mind trying to analyse yourself, because there is not many people can do that, it's the hardest analysation there is." AA022
Focus groups
Content Information and support in relation to both BD and anxiety Recognition of the positive emotions associated with overcoming challenging situations and providing support to address these Genuine collaboration around treatment targets and potential outcomes Opportunities for family or key clinician to attend key sessions to support change "If a therapist is aware of the bipolar running alongside the anxiety erm they'll probably get less frustrated, and there might be tools that they can help …" P006 "There'd be nothing wrong in you saying 'this is how I want this to go' . And someone else might want it to go a different way and they'd be able to negotiate it at that time rather that it being built." P001 "Yeah. But it has to be my set of goals. Not you coming in and saying 'Right I want you to be mood free … in 6 weeks' time' ." P002 Support materials Flowcharts/work sheets to self-monitor progress in therapy and as a posttherapy resource Engaging support materials including lived experience accounts and links to other resources/organizations "…and the worksheets as well, you know, when I was in the mood, even though a couple of weeks later it might not felt like it was working again, you can … keep going back to it". P004 "But in a manual you can go back in to tap in and tap out of, I think it's a good idea. …. So if you can keep going back to it 'cause we don't always get the computer up." P005
Barrier and facilitators
Importance of timely access to therapy Support for time limited approach deliverable by a range of disciplines to minimize waiting lists.
"Yes, getting through the GP to get the referrals there is not an awful lot of places now and waiting lists are ridiculously long." P004 "We'd want you to be able to quantify it at the end of your 10 weeks or whatever and say well this is what you expected to get out of it. Did you or didn't you?" P007 I think it would be really important for anyone delivering the programme, which sounds really good, you know, if you can get social workers and nurses and everyone to learn a package or whatever" P001 finally drawn into an anxiety recovery plan highlighting key challenges for the client and which techniques they had selected to be useful in addressing them (including strategies already successfully used by the client and new strategies developed in therapy). The relative emphasis between anxiety and mood strategies varied between clients based on their individual goals and formulation. 
TA B L E 2 Phases of treatment of anxiety in context of bipolar disorder (AIBD)
Phase Focus/content "Sarah" "James" 
Therapists
AIBD was delivered by three therapists; all met BABCP accreditation criteria, trained in AIBD, and received weekly clinical supervision from SJ. 
Primary feasibility and acceptability outcomes
Qualitative interviews
A nested qualitative study was conducted with 17 therapy participants (purposively sampled on age and gender, HADS-A score at recruitment, number of sessions attended, and previous relapse history) to explore subjective experiences of AIBD.
Clinical outcomes
Face-to-face assessments were conducted at initial interview (to confirm diagnosis), baseline, 16, 48, and 80 weeks: interim telephone assessments at 32 and 64 weeks. Observer ratings were obtained at each assessment. Self-report measures were not obtained at interim assessments.
Primary clinical outcome was impact of AIBD on observer-and Spielberger, 1983) , time to relapse, and symptoms of mania and depression (SCID for DSM-IV Longitudinal Interval Follow-up Evaluation (First et al., 1997; Keller et al., 1987) , Hamilton Depression Rating Scale (Hamilton, 1960) , and 
Data analysis
Primary outcome information on recruitment and retention levels, therapy fidelity, alliance, acceptability, and completion were all summarized with descriptive statistics. Sample characteristics including baseline mood and anxiety were reported.
The clinical and functional outcome measures were analyzed using the methods that would be employed in a full trial. The intentionto-treat principle was employed throughout. For the time to relapse survival analyses, covariates were treatment arm, gender, number of previous bipolar episodes (8-20 and more than 20, both versus 1-7), and baseline HAM-A total in a cox regression model.
A two-level linear mixed model was fitted with time as a discrete covariate and an unstructured covariance matrix at level 2 using the mixed procedure in StataCorp (2015) . This model corresponds to a repeat measure model but allows for missing data at some time points, enabling subjects with incomplete data to be included in the analysis. The normality assumption of these models was checked using a normal probability plot of model residuals. A model with a discrete time by treatment interaction was fitted to estimate the treatment effect and the 95% confidence interval at each follow-up time point (Model 1). If there was no interaction at the 5% level based on a Wald test, the interaction term was omitted and the overall treatment effect was estimated from this simpler model (Model 2). The same covariates described above were used for these models, additionally adjusting for baseline value of the outcome. A baseline response by discrete time interaction term was also included.
Qualitative interviews were audio-recorded, transcribed verbatim, and thematically analyzed to explore participants' experiences of AIBD (Braun & Clarke, 2006) . Themes were compared against the data using a constant comparative approach by a multidisciplinary panel (CH, SP, LR, SJ, and RL). Interviews were conducted until thematic saturation was achieved.
RESULTS
Participants
Participants were mainly white British females with a chronic course of BD (>70% had over 20 mood episodes at baseline, Table 3) aged over 40 years (AIBDx = 45.5, SD = 10.7; TAUx = 42.9, SD = 16.6).
The majority had a bipolar I diagnosis (n = 62, 86%), were either divorced or never married (n = 48, 67%), and parents (n = 42, 58%).
Although most participants had at least commenced further education (n = 55, 76%), only a minority were in employment (n = 28, 39%). Of those not in work, the majority were in receipt of sickness/disability benefits (n = 23 of 44, 52%). Comparing AIBD with TAU, the only substantial differences were in relationship status (twice as many married or cohabiting in AIBD), employment (approximately 10% more AIBD participants in work), and referral source (two thirds of referrals in AIBD were self-referrals compared with one third of TAU).
At baseline, consistent with HADS-A screening, 85% of participants met criteria for at least one current anxiety disorder; generalized anxiety disorder and social phobia were the most common (Table 2 ).
More AIBD participants met criteria for two or more anxiety disorders (59% vs. 40%). Rates of social phobia, agoraphobia, posttraumatic stress disorder (PTSD), panic ± agoraphobia, and specific phobia were all numerically higher in AIBD versus TAU.
STAI-S and STAI-T scores at baseline (Table 6) were elevated compared with general populations and anxiety group norms 1 (Spielberger, 1983) : HAM-A scores were in the normal range.
Observer-rated measures indicated very mild depression HAM-D (Hamilton, 1960; Zimmerman, Martinez, Young, Chelminski, & Dalrymple, 2013) and extremely low mania scores (MAS) (Bech, 2012) at baseline (both arms).
Personal recovery scores were higher at baseline than in a previous RCT for BD (Jones et al., 2015) . Quality of life (QoL-BD) was similar to that reported in the measure development paper (Michalak et al., 2010) ; personal and social functioning (PSP) indicated no more than mild impairment in functioning (Morosini et al., 2000) .
Primary outcomes 3.2.1 Feasibility and acceptability
Figure 1 presents recruitment and retention rates according to CONSORT criteria (Schulz, Altman, & Moher, 2010) . Of 122 people screened, 14 declined, nine were uncontactable, and 27 did not meet study inclusion criteria. Of 72 randomized participants, 32 (44%) were recruited by clinician referral. Twenty-five AIBD participants came via self-referral (62.5%), compared to 15 (37.5%) TAU (see Table 3 ).
Recruitment target was met (n = 72; 59% of those screened for eligibility). Retention was 88% (n = 63) to end of therapy (16 weeks), 78% (n = 56) to 32-week follow-up, 75% (n = 54) to 48-and 64-week follow-up, and 74% (n = 53) to 80-week follow-up (feasibility target 75 ± 10% to 80 weeks ). Retention rates are at least as high in TAU as in AIBD (Figure 1 ). Measure completion rates for retained participants varied from 97% at baseline to 79% at 80 weeks (Table 4) .
Single unblindings were reported in seven AIBD and four TAU participants: an alternate blind RA was allocated in each case. Two participants lost to follow-up died during the final follow-up period for reasons unrelated to the trial. 
TA B L E 3
Client ratings of therapy
AIBD clients rated therapy on two 0-10 scales. First, how helpful they thought the therapy was 0 (not at all) to 10 (extremely); second, whether they would recommend it to someone with similar problems 0 (definitely not) to 10 (definitely yes). Data were available for 21 participants: experience of therapy averaged 9.14 (SD 0.55); likelihood of recommending the therapy averaged 9.26 (SD 0.70).
Qualitative interview findings
Participants indicated they valued the intervention in contrast with previous forms of support received (see Table 5 for illustrative quotes).
They identified benefits of treating anxiety and BD together in contrast with previous experiences of having these problems addressed separately. AIBD is relatively brief; several participants found this helpful in providing a clear structure and personally identified targets. However, others wished therapy had been longer, although without specifying omissions from therapy as delivered. Coping strategies learnt in AIBD were helpful in (1) overcoming anxiety-based social isolation and functional limitations and (2) increasing confidence in dealing with BD.
Secondary self-and observer-reported outcome measures
Key clinical outcomes were anxiety symptoms, subsyndromal mood symptoms (see Tables 6 and 7) , and time to relapse (Figures 2-4) . The 
DISCUSSION
This paper reports the first RCT feasibility study of a novel psychological intervention for anxiety in BD. The approach is feasible: 59% of screened participants were randomized to feasibility trial, which compares well with previous CBT for BD trials (Jones et al., 2015; Lam, Hayward, Watkins, Wright, & Sham, 2005; Scott et al., 2006) . Retention rate to 80 weeks was 72%, within the target of 75 ± 10% and comparable to other CBT trials in BD: 67% follow-up to 15 months (Jones et al., 2015) and 75% follow-up to 18 months (Scott et al., 2006) .
Furthermore, retention was broadly balanced across arms, indicating absence of resentful demoralization (Brewin & Bradley, 1989) . No trialrelated adverse events were reported. The arms did differ in referral Benefits of treating anxiety and BD together "Normally people do them separately and trying to put them together when you are ill is just… not easy at all… if you have got them separate it's like skirting round each issue, but putting them together …….. a person that deal with them all, and will go slowly over everything so you know what to expect, it is so much better, definitely." (AN007)
Treatment duration "it was 10 sessions, and that were it, but the 10 sessions meant that the goals that were laid out at session one, those were the goals that were worked at, and those were the goals that were achieved by the end and that is a far better way of working." (AN001) "I remember thinking I didn't want them to come to an end. But I couldn't have told you, or couldn't have probably pinpointed aspects that I needed more to cover I think I was just… gaining so much that I kind of felt maybe there was more to gain as well you know if I had carried on." (AN008) "it's good when you have the sessions but once they finish you feel, I felt like lost, and CBT is ok during treatment but long term, putting it into practice day to day, you know it's difficult to remember instantly all the tips, and that." (AN006)
Benefits of coping strategies "it has been crippling for me over the years. I have had a number of breakdowns, and each time it's always been the anxiety that has kept me prisoner in my own home, it has stopped me from socialising, and progressing so this time, I have healed better and with coping strategies that have allowed me to do things, a lot quicker than before." (AN008) "prior to becoming part of this study I thought my bipolar disorder owned me… and was in control of me and I had no control over it… and through this study, now I own it and I control it… I… through this study and through the work that I did with route with more participants in the therapy being recruited through self-referral. However, both arms were similar in terms of demographic characteristics except for the larger proportion of the therapy arm who had ≥ 2 anxiety disorders.
Participants were over 40 years old and over two thirds had at least 20 prior episodes, more than those reported in some specific relapse prevention trials (Lam et al., 2005; Meyer & Hautzinger, 2012) . Only one third of the participants were in work, with most others in receipt of sickness/disability benefits.
Eighty-five percent of participants met criteria for anxiety disorders. Mood symptoms were low throughout and participants were relatively high functioning on personal recovery, quality of life, and personal and social functioning measures. Participants attended 77%
of AIBD sessions offered, indicating a significant commitment to AIBD. Several previous BD therapy trials did not specify attendance rates (Lam et al., 2003; Scott et al., 2006) . Meyer and Hautzinger (2012) reported that 14.5% of therapy participants attended <80% of sessions, the majority of whom attended <50%. More specific data indicated individual recovery therapy attendance of 78% of sessions (Jones et al., 2015) . Thus, AIBD attendance rates are comparable with the published literature. Acceptable therapeutic alliance and therapy fidelity were achieved. Client ratings of therapy usefulness and likelihood of recommending therapy were high (average >9/10 in both cases) but available for only 21 of 37 AIBD participants and so not definitive. In-depth qualitative interviews indicated the participants valued AIBD, linked to improvements in both symptoms and functioning in a number of clients. Some participants wanted a longer intervention, although others were happy with it as delivered. Personal recovery (BRQ) but not personal and social functioning (PSP) improved more rapidly for participants in AIBD during therapy, while Qol.BD was numerically improved to 48 weeks but gains were not sustained at later follow-up.
Mood relapse rate was lower than that reported by Meyer and Hautzinger (2012) (64.5% at 80 weeks) and Lam et al. (2005) (75% at 30 months) and comparable to Scott et al. (2006) (52% at 18 months).
Although numerically higher in AIBD arm, the hazard ratio did not approach statistical significance.
Overall, the current findings support the feasibility and acceptability of the trial design and the AIBD intervention. However, it is important to acknowledge the lack of signal overall for the trial based on current findings. This suggests building on evidence for the impor- a Based on a model with a treatment by discrete time interaction differences are between AIBD and TAU adjusting for sex, number of previous bipolar episodes, baseline HAM-AD anxiety subscale, the baseline score, and the interaction between the baseline score and discrete time. * The P-value for the overall treatment by time interaction. M1 includes a time by treatment interaction; M2 omits the interaction.
both have more female and predominantly white participants, it is not possible to compare clinical severity with respect to prior mood episodes or current anxiety disorders as these were not reported by may improve anxiety symptoms in cyclothymia, among other bipolar spectrum conditions, but that development of both psychological models and treatment protocols specific to anxiety in BD are a priority (Stratford et al., 2015) .
There is accumulating evidence that individuals with BD typically respond to psychological therapy better when delivered earlier in the course of their disorder. This has been reported in relation to CBT and group psychoeducation and is consistent with recent positive outcomes for a trial of recovery-focused therapy for recent onset BD (Jones et al., 2015; Scott et al., 2006) . It is therefore possible that focusing the intervention in the future more clearly on individuals with more recent onset BD might lead to stronger clinical effects.
Although we considered post hoc additional exploratory analysis of the relationships between severity and outcome in the current sample, we concluded that this would be inappropriate with a relatively small participant group, consistent with recent CONSORT guidance (Eldridge et al., 2016) .
Strengths included comprehensive participant assessment, extensive follow-up postintervention, and use of mixed methods to explore participants' therapy experiences.
The trial was successful in demonstrating feasibility and acceptability of selection, recruitment, and intervention procedures. People took therapy when offered, and retention was acceptable. Secondary clinical data present a mixed picture, with most promising outcomes in selfreported anxiety and quality of life. RCTs of CBT for anxiety typically report follow-up period up to 48 weeks, which may be appropriate for a future AIBD trial (Covin, Ouimet, Seeds, & Dozois, 2008) . Although AIBD was generally well received, some participants wanted more sessions. Extending AIBD to 12-15 sessions would be consistent with NICE guidance interventions for anxiety (NICE, 2011) . More robust clinical outcomes might be obtained by opting for more restrictive inclusion criteria particularly with respect to duration of BD course. If successful, a definitive trial employing a revised version of the AIBD intervention would provide a timely addition to therapeutic options for BD consistent with the importance of anxiety in NICE BD guidelines (NICE, 2014) .
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